Concord Biotech shares fell 16% to Rs 1,777.7 after the company reported a 2.1% YoY decline in Q3 FY25 net profit to Rs 75.92 ...
Stocks surged across major indices after positive inflation data and a memo from President Trump on trade tariffs. Strong gains were seen in computer hardware, telecom and biotech sectors while bond ...
Nano-X Imaging is a disruptive biotech investment. The AI push in the health sector is a long-term tailwind. See why we rate ...
Zacks Investment Research on MSN13h
Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 GuidanceIt was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...
Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...
The aggregate gross proceeds to the Company from the offering were approximately $1,050,000, before deducting the placement ...
A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...
Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Vir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback